The Changing Landscape of Pharmacotherapy for Diabetes Mellitus: A Review of Cardiovascular Outcomes
The prevention of cardiovascular morbidity and mortality has always been a primary concern in patients with type 2 diabetes. Modern trials of glucose-lowering therapies now assess major adverse cardiac events as an endpoint in addition to the effects on glycaemic control. Whilst the data on the effi...
Main Authors: | Linda Wu, Jenny E. Gunton |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2019-11-01
|
Series: | International Journal of Molecular Sciences |
Subjects: | |
Online Access: | https://www.mdpi.com/1422-0067/20/23/5853 |
Similar Items
-
Important Considerations for the Treatment of Patients with Diabetes Mellitus and Heart Failure from a Diabetologist’s Perspective: Lessons Learned from Cardiovascular Outcome Trials
by: Chrysi Koliaki, et al.
Published: (2019-12-01) -
Cardiovascular death risk reduction in type 2 diabetes patients with confirmed cardiovascular diseases
by: Е. V. Shlyakhto, et al.
Published: (2018-09-01) -
National advisory board on diabetes mellitus: unsolved issues and new opportunities for diabetes treatment
by: Gagik Radikovich Galstyan
Published: (2014-08-01) -
The impact of cardiovascular co-morbidities and duration of diabetes on the association between microvascular function and glycaemic control
by: F. Casanova, et al.
Published: (2017-09-01) -
Glycaemic variability in diabetes: a tool for assessing the quality of glycaemic control and the risk of complications
by: Vadim Valer'evich Klimontov, et al.
Published: (2014-04-01)